Table 4.
No. | MPS type | Gender | DXA | Age (yr) | ERT duration (yr) | Height z score | Weight z score | BMI z score | BMD (g/cm2) | BMD z score | HAZ adjusted BMD z score |
---|---|---|---|---|---|---|---|---|---|---|---|
The initiation of ERT at pre-pubertal age |
|
||||||||||
1 |
MPS II (M*) |
M |
Baseline |
5 |
2.5 |
−1.63 |
−0.69 |
−0.17 |
0.53 |
−0.81 |
−0.31 |
Follow-up |
7.5 |
−1.22 |
−0.77 |
−0.39 |
0.561 |
−1.48 |
−1.01 |
||||
2 |
MPS VI |
M |
Baseline |
6.6 |
3.8 |
−3.69 |
−1.69 |
0.17 |
0.496 |
−1.65 |
−0.26 |
Follow-up |
10.4 |
−5.92 |
−1.82 |
0.11 |
0.51 |
−2.75 |
0.09 |
||||
3 |
MPS VI |
M |
Baseline |
8.7 |
5.1 |
−6.52 |
−1.69 |
1.29 |
0.442 |
−2.35 |
0.49 |
Follow-up |
13.8 |
−7.83 |
−2.55 |
0.16 |
0.492 |
−3.20 |
1.25 |
||||
4 |
MPS VI |
F |
Baseline |
11.7 |
7.4 |
−5.88 |
−1.57 |
1.18 |
0.65 |
−2.05 |
1.07 |
Follow-up |
19.1 |
−8.7 |
−2.23 |
2.06 |
0.671 |
−3.10 |
2.83 |
||||
5 |
MPS II (M*) |
M |
Baseline |
13.2 |
4.5 |
−2.77 |
−1.12 |
0.00 |
0.636 |
−2.07 |
−0.50 |
Follow-up |
17.7 |
−3.2 |
−0.68 |
0.51 |
0.867 |
−3.99 |
−1.76 |
||||
The initiation of ERT at post-pubertal age |
|
||||||||||
6 |
MPS II (M*) |
M |
Baseline |
17.5 |
1.0 |
−4.47 |
−1.84 |
−0.62 |
0.774 |
−5.06 |
−2.02 |
Follow-up |
18.5 |
−3.97 |
−1.62 |
−0.49 |
0.796 |
−4.80 |
−1.99 |
||||
7 |
MPS I (H/S**) |
M |
Baseline |
18.5 |
5.3 |
−7.69 |
−2.13 |
0.53 |
0.648 |
−6.51 |
−1.18 |
Follow-up |
23.8 |
−7.23 |
−1.77 |
1 |
0.769 |
−5.11 |
NA |
||||
8 |
MPS VI |
F |
Baseline |
22.8 |
4.5 |
−8.88 |
−3.25 |
−0.11 |
0.712 |
−2.82 |
NA |
Follow-up | 27.3 | −9.77 | −3.14 | 0.81 | 0.789 | −2.3 | NA |
MPS, mucopolysaccharidoses; M*, mild form; H/S**, Hurler/Scheie; DXA, dual energy x-ray absorptiometry; ERT, enzyme replacement therapy; z score, standard deviation score; BMI, body mass index; BMD, bone mineral density; HAZ, height-for-age z score; NA, not available.